William Harlan, MD
Gastroenterology · Asheville, NCNPI 1003806043
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,418 of the $4,923 with a category attached, or 89.7%. 23 manufacturers reported payments, led by AbbVie at 51.7% of the total. 2025 is the largest year on record at $1,951, more than ten times the $159 reported in 2019.
Across 130 payments — averaging $37.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$753
- QOL Medical, LLC$168
- Sanofi$163
- Enterra Medical, Inc.$145
- Ardelyx, Inc.$144
- plus $1K from 17 others
Across 226 payments — averaging $6175.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$612K
- AbbVie$230K
- Genentech, Inc.$135K
- Eli Lilly$113K
- Janssen Research & Development, LLC$92K
- Bristol Myers Squibb$91K
- plus $122K from 7 others
What the payments were for
- Consulting fees$46910%
- Food & beverage$4,41890%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,923 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi On-BodyRisankizumab-Rzaa | 32 | $692,771 |
| Humira(Cf) PenAdalimumab | 42 | $526,774 |
| LinzessLinaclotide | 28 | $26,184 |
| MotegrityPrucalopride Succinate | 15 | $12,985 |
| Mesalamine | 37 | $9,016 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 32 | $3,796 |
| Colestipol Hcl | 29 | $3,506 |
| Balsalazide Disodium | 14 | $2,824 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 25 | $1,795 |
| Sodium Chloride0.9 % Sodium Chloride | 44 | $1,778 |
| Budesonide EcBudesonide | 13 | $1,510 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $1,338 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 61 | $1,169 |
| Famotidine | 73 | $929 |
| Omeprazole | 97 | $859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,543 | $26,18428 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $99 | $12,98515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Asheville
- Adam ZivonyAsheville$184K
- Brian GarvinAsheville$103K
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Robert ReindollarSalisbury$430K
- Andrew StormWinston Salem$426K
- John PoulosFayetteville$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.